en.Wedoany.com Reported - Olivier Laczka, CEO of Australian biotechnology company Noxopharm Limited, introduced new advances in its Sofra™ technology platform. The company has discovered a regulatory method based on Toll-like receptor 8 (TLR8), offering new possibilities for treating cancer and chronic inflammatory diseases.

In collaboration with scientists from the Hudson Institute of Medical Research, Noxopharm has developed a novel approach to modulating immune responses using small RNA oligonucleotides. The company is currently advancing a topical treatment for cutaneous lupus erythematosus, aimed at directly targeting skin inflammation. Compared to traditional corticosteroid therapies, this approach avoids the severe side effects associated with long-term use.

In the field of immuno-oncology, Sofra-derived oligonucleotides can enhance TLR8 activity. New research data shows that a proprietary TLR8-enhanced oligonucleotide can boost the activity of a clinical-stage TLR8 agonist by more than 200-fold in human skin biopsy samples.

The interview also covered upcoming clinical milestones, strategic collaborations, delivery technologies, and the company's plans to generate efficacy data in patients over the coming months.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com